Speculating in Takeover Targets Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets

ULBI 6.350

+0.3%

Feb 11 3:57 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: richardred	2/14/2005 1:37:32 PM
	of 7265

Boston Scientific Has Leeway To Pursue Mergers 02.14.05, 12:26 PM ET Goldman Sachs reiterated an "outperform" rating on Boston Scientific (nyse: BSX - news - people ), saying the company's merger agreement with Advanced Bionics won't limit Boston Scientific's future merger opportunities. "Our interpretation of the merger document language is that Boston Scientific still has considerable leeway in considering M&A activity in the neuromodulation market," Goldman said. The research firm said rumors of consolidation in the sector began when Cyberonics (nasdaq: CYBX - news - people ) indicated an interest in forging a strategic alliance with another company. According to Goldman, Advanced Bionics produces technology that stimulates a different nerve than the Cyberonics product does. Other companies that have expressed interest in the neuromodulation sector are Medtronic (nyse: MDT - news - people ) and Johnson & Johnson (nyse: JNJ - news - people ). For fiscal 2005 and 2006, Goldman estimates earnings per share for Boston Scientific of $2.10 and $2.33, respectively. forbes.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next